GlassScriptPhysician profile
James S Mcclellan, III
NPI 1124089073
$11,346.86
in general payments reported to CMS, 2019-2025
41 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,494 · 2020: $1,101 · 2021: $1,693 · 2022: $1,738 · 2023: $1,791 · 2024: $1,698 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,246 · Consulting Fee: $60.46 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,245.80 |
| Consulting Fee | $60.46 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,285.14 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,053.26 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $736.90 | 2019-2025 | |
| Amgen INC. | $696.33 | 2021-2025 | Tezspire |
| Csl Behring | $644.56 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Pfizer INC. | $610.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $605.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $557.85 | 2020-2025 | Cuvitru, Eohilia, Takhzyro |
| Genentech USA, INC. | $514.32 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $380.34 | 2019-2024 | Dupixent |
| Abbvie INC. | $310.96 | 2021-2025 | |
| Pharming Healthcare, INC. | $263.38 | 2022-2025 | Ruconest, Joenja |
| Teva Pharmaceuticals USA, INC. | $155.13 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.28 | 2020-2023 | Spiriva Respimat |
| Shire North American Group INC | $140.22 | 2019 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $122.78 | 2023-2024 | Ayvakit |
| Organon LLC | $95.70 | 2025 | Vtama |
| Adma Biomanufacturing LLC | $93.33 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $92.49 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $85.34 | 2025 | Neffy |
| Kaleo, INC. | $82.51 | 2019-2023 | Auvi-Q |
| Grifols USA, LLC | $81.05 | 2022-2023 | Xembify |
| Ionis Pharmaceuticals, INC. | $64.70 | 2025 | Dawnzera |
| Leo Pharma INC. | $60.66 | 2022-2025 | Adbry, Anzupgo |
| Welch Allyn | $58.30 | 2021 | |
| Alk-Abello, INC | $57.43 | 2020-2025 | Alternaria Tenuis, Pre-Pen, Timothy, Standardized |
| Bio Products Laboratory USA, INC. | $52.11 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $42.60 | 2019 | |
| Mylan Specialty L.P. | $25.82 | 2019-2020 | |
| Octapharma USA, INC. | $25.55 | 2019 | |
| Lilly USA, LLC | $22.24 | 2024 | Ebglyss |
| Verona Pharma, INC. | $20.47 | 2025 | Ohtuvayre |
| Dermavant Sciences, INC. | $19.54 | 2024 | Vtama |
| Insmed, INC. | $18.91 | 2024 | Arikayce |
| Incyte Corporation | $18.67 | 2023 | Opzelura |
| Circassia INC. | $18.17 | 2019 | |
| Merck Sharp & Dohme LLC | $17.50 | 2021 | |
| Galderma Laboratories, L.P. | $17.27 | 2025 | Nemluvio |
| Uswm, LLC | $16.00 | 2021 | |
| Hospira, INC. | $14.40 | 2024 | |
| Biocryst US Sales Co., LLC | $14.25 | 2023 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcclellan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.